NANO Nanobiotix SA

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at following conference:

H.C. Wainwright 27th Annual Global Investment Conference

Date: Tuesday, September 9th, 2025

Time: 9:00 am EDT / 3:00 pm CEST

Location: New York, NY

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix & Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link:

The fireside chat will be webcast live from the  of the Investors section of the Company’s website. The replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at or follow us on and .

Contacts

Nanobiotix
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

Investor Relations Department



Joanne Choi

VP, Investor Relations (US)

+1 (713) 609-3150



Ricky Bhajun

Director, Investor Relations (EU)

+33 (0) 79 97 29 99



Media Relations




France – HARDY

Caroline Hardy

50

Global – LifeSci Advisors

Kevin Gardner

+1 (617) 283-2856

  

 

Attachment



EN
02/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global In...

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at following conference: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9th, 2025Time: 9:00 am EDT / 3:00 pm...

 PRESS RELEASE

Nanobiotix participera à la conférence investisseurs annuelle H.C. Wai...

Nanobiotix participera à la conférence investisseurs annuelle H.C. Wainwright global investment PARIS et CAMBRIDGE, Mass., 02 sept. 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui que Nanobiotix participera à une discussion (« fireside chat ») à la conférence suivante : Conférence H.C. Wainwright 27th Annual G...

 PRESS RELEASE

Information mensuelle relative au nombre total de droits de vote et d’...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 27 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable231 juillet 202548 236 67150 340 73650 318 618 À ...

 PRESS RELEASE

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable2July 31, 202548,236,67150,340,73650,318,618 About NANOBIOTIX ...

Heidi Mo Jinghui ... (+2)
  • Heidi Mo Jinghui
  • John Cheong Ming Chern

Nanofilm Technologies International Ltd - 1H25: Revenue In Line But Ea...

Nanofilm’s 1H25 revenue of S$107m (+30% yoy) met our expectation, forming 46% of our full-year estimate. However, earnings remain soft, at only S$1.6m or 12% of our full-year estimate (vs S$3.7m loss in 1H24) due to a softer gross margin. Revenue growth was driven by the AMBU and IEBU segments. Nanofilm expects consistent growth in 2025. Although Nanofilm’s revenue is healthy, it may take time to achieve meaningful earnings. Maintain SELL with a 22% higher target price of S$0.56.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch